Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • About Us
    • About Molecular Pharmacology
    • Feedback
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • About Us
    • About Molecular Pharmacology
    • Feedback
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Rapid CommunicationAccelerated Communication

Neuroprotection against Oxidative Stress by Estrogens: Structure-Activity Relationship

Christian Behl, Thomas Skutella, Frank Lezoualc’H, Anke Post, Martina Widmann, Christopher J. Newton and Florian Holsboer
Molecular Pharmacology April 1997, 51 (4) 535-541; DOI: https://doi.org/10.1124/mol.51.4.535
Christian Behl
1Max Planck Institute of Psychiatry, Clinical Institute, 80804 Munich, Germany (C.B., F.L., A.P., M.W., C.J.N., F.H.), and 2Institute of Anatomy, Charité Berlin, 10098 Berlin, Germany (T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Skutella
1Max Planck Institute of Psychiatry, Clinical Institute, 80804 Munich, Germany (C.B., F.L., A.P., M.W., C.J.N., F.H.), and 2Institute of Anatomy, Charité Berlin, 10098 Berlin, Germany (T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Lezoualc’H
1Max Planck Institute of Psychiatry, Clinical Institute, 80804 Munich, Germany (C.B., F.L., A.P., M.W., C.J.N., F.H.), and 2Institute of Anatomy, Charité Berlin, 10098 Berlin, Germany (T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anke Post
1Max Planck Institute of Psychiatry, Clinical Institute, 80804 Munich, Germany (C.B., F.L., A.P., M.W., C.J.N., F.H.), and 2Institute of Anatomy, Charité Berlin, 10098 Berlin, Germany (T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martina Widmann
1Max Planck Institute of Psychiatry, Clinical Institute, 80804 Munich, Germany (C.B., F.L., A.P., M.W., C.J.N., F.H.), and 2Institute of Anatomy, Charité Berlin, 10098 Berlin, Germany (T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J. Newton
1Max Planck Institute of Psychiatry, Clinical Institute, 80804 Munich, Germany (C.B., F.L., A.P., M.W., C.J.N., F.H.), and 2Institute of Anatomy, Charité Berlin, 10098 Berlin, Germany (T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florian Holsboer
1Max Planck Institute of Psychiatry, Clinical Institute, 80804 Munich, Germany (C.B., F.L., A.P., M.W., C.J.N., F.H.), and 2Institute of Anatomy, Charité Berlin, 10098 Berlin, Germany (T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Oxidative stress-induced neuronal cell death has been implicated in different neurological disorders and neurodegenerative diseases; one such ailment is Alzheimer’s disease. Using the Alzheimer’s disease-associated amyloid β protein, glutamate, hydrogen peroxide, and buthionine sulfoximine, we investigated the neuroprotective potential of estrogen against oxidative stress-induced cell death. We show that 17-β-estradiol, its nonestrogenic stereoisomer, 17-α-estradiol, and some estradiol derivatives can prevent intracellular peroxide accumulation and, ultimately, the degeneration of primary neurons, clonal hippocampal cells, and cells in organotypic hippocampal slices. The neuroprotective antioxidant activity of estrogens is dependent on the presence of the hydroxyl group in the C3 position on the A ring of the steroid molecule but is independent of an activation of estrogen receptors.

Ovarian steroids are of prime importance in the normal maintenance of brain function; the loss of these steroids at menopause may account, at least in part, for the cognitive decline and neurodegeneration that are associated with AD (1). Consistent with this are the results of population-based studies, which suggest that the increased incidence of AD in older women may be caused by the deficit of the female sex hormone estrogen after menopause and that the use of estrogen during the postmenopausal period can delay the onset and lower the risk of AD (2). Estrogen acts on a number of different target organs, including the brain, that express specific estrogen receptors, and it is a key modulator of processes involved in differentiation, homeostasis, and development of the female reproductive function (3, 4). In addition to a genomic mode of action via transcriptional activation, estrogen and other steroids, such as progesterone derivatives, have been found to produce short term nongenomic actions. These include the modulation of the electrical properties of neurons and of transmitter release processes (5). The nongenomic antioxidant activity of estrogens has received increasing attention recently (6). Oxidative stress and free radical-mediated cell death have been linked to diseases such as atherosclerosis (7) and to a number of neurodegenerative disorders such as Parkinson’s disease and AD (8-11).

Because it has been suggested that estrogens, in contrast to all other natural steroids, are antioxidants of membrane phospholipid peroxidation in cell free systems because of their phenolic structure (6), and because initial data indicate a neuroprotective effect of 17-β-estradiol in vitro (12, 13), we investigated the neuroprotective potential of estrogen and some of its derivatives against oxidative stress-induced neurodegeneration. Oxidative damage and lipid peroxidation can be caused by the neurotoxic amyloid β protein (11) that accumulates in plaques in the brains of AD patients (14) or by excitatory amino acids such as glutamate, which has also been implicated in various neurodegenerative diseases (15), via a glutamate receptor-dependent (16) or a glutamate receptor-independent pathway (17, 18). The latter can be mediated through the induction of an imbalance in antioxidant enzyme systems followed by a reduction in the levels of intracellular antioxidant glutathione in neurons (17,18). The main goals of this study were 1) to investigate any possible protective effects of estrogen for neurons and 2) to identify a possible structure-activity relationship. Therefore, we tested 17-α-estradiol, 17-β-estradiol, estriol, estrone, ethinyl estradiol, mestranol, quinestrol, and the catechol estrogens 2-OH-estradiol and 4-OH-estradiol (Fig. 1) for their neuroprotective potential against the oxidative stressors Aβ and H2O2. The latter is a mediator of Aβ toxicity (11) and a precursor of highly oxidizing, tissue-damaging radicals such as the lipid peroxidizing hydroxyl radical (19). In addition, glutamate and BSO, which blocks the de novo biosynthesis of glutathione (19), were used.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Molecular structure of estrogens and estrogen derivatives used in the experiments. The 3-OH group on the A ring of the steroid molecule necessary for the neuroprotective activity is highlighted.

Experimental Procedures

Materials, cell lines, and cell culture.

Cells were cultured in DMEM supplemented with 10% fetal calf serum under standard culture conditions. Rat primary cultures from E19 embryonic hippocampi and mouse primary cortical neurons from E19 embryonic cortices were prepared as previously described (11, 21). Primary cells were cultured on poly-l-lysine–coated dishes in a 50% DMEM/50% Ham’s F12 medium that contained N2 supplements. Under these minimal culture conditions, more than 90% of the cells were stained positive for neuron-specific enolase. Primary neurons were used after 7–10 daysin vitro. Mouse clonal hippocampal HT22 cells were cultivated in DMEM supplemented with 10% fetal calf serum. All media, sera, and medium supplements were from GIBCO (Eggenstein, Germany). The amyloid β protein used (fragment 25–35) was from Bachem/Saxon (Hannover, Germany). Glutamate, H2O2, and BSO were from Sigma (Deisenhofen, Germany), as were all other chemicals. Stock solutions for the toxins were prepared and diluted in H2O.

Cytotoxicity and viability assays.

Cell viability was assessed using a modified MTT assay as previously described (9, 11,12). Cell lysis induced by different toxins was assessed with the trypan blue exclusion test followed by cell counting (11, 12). In addition, the fluorescing DNA label PI was used to differentiate between dead cells and living cells (12). All toxicity assays were repeated five times in triplicate determinations. For trypan blue and PI stainings, cells were plated in 60-mm dishes, and the different reagents were added. After 24 hr, trypan blue (at a concentration of 0.12%) or PI (at a concentration of 5 μg/ml) was added, and the number of viable cells (trypan blue-excluding or PI-negative) per low magnification field were determined. For statistical comparisons, analysis of variance followed by a Scheffe’s post hoc test was used.

Preparation and culture of organotypic hippocampal slices.

Organotypic hippocampal slices were prepared and maintained as previously described (24). Briefly, after decapitation, the brains of 5- to 6-day-old male Sprague-Dawley rats were removed and transferred to cold DMEM. Using a tissue chopper, the hippocampus and the entorhinal cortex were cut into 250-μm slices and were placed on a sterile, porous (0.4 μm) membrane (Millicell; Millipore, Eschborn, Germany). The membranes were transferred into a tissue culture plate and covered with culture medium (final volume 1 ml). The culture medium consisted of 50% DMEM, 25% horse serum, 25% Hanks’ balanced salts, and 100 units/ml penicillin/100 μg/ml streptomycin. The culture medium was changed routinely three times a week. Slice cultures were used for experiments after 14 days in vitro.

Detection of intracellular H2O2 and related peroxides.

The formation of intracellular peroxides was detected by using DCF-DA as previously described (11, 17). DCF-DA is a nonfluorescent compound that, upon entering cells, is de-esterified and then becomes a substrate to oxidation by intracellular H2O2 and related peroxides. Primary cortical neurons or clonal hippocampal HT22 cells were plated, and toxins were added. After 6 hr, 10 μm DCF-DA was added for 1 hr at 37°. Then, the cells were washed with phenol red-free HEPES-buffered DMEM supplemented with 2% fetal calf serum, and the cultures were viewed with a fluorescence microscope using fluorescein optics. Cultures were compared with treatment condition by an observer blinded to the study, and fluorescence was determined qualitatively by counting the cells first under PC and then under fluorescence. For quantification, >200 cells per low magnification field were counted in five separate experiments, fluorescing cells were determined, and results were expressed as the percentage of fluorescent cells.

Results and Discussion

Rat primary hippocampal neurons and mouse clonal hippocampal HT22 cells pretreated for 20 hr with 10 μm 17-β-estradiol, estriol, or estrone and with the nonestrogenic stereoisomer 17-α-estradiol, which does not bind to estrogen receptors and is therefore biologically inactive (20), were protected against a 24-hr challenge by Aβ25–35 (2 μm), the toxic fragment of Aβ (21) (Fig. 2, A and B). Cells of both of these hippocampal cell culture systems were also protected against H2O2 (30 μm or 60 μm) and BSO (500 μm) by these estrogens (Table 1 and data not shown). A significant increase in cell survival (p < 0.01) could only be observed at the 10-μm concentration of these estrogens. Lower concentrations were not effective, as shown in detail for the survival of HT22 cells that were pretreated with ethinyl estradiol after a challenge with either BSO, Aβ25–35, or glutamate (Fig. 2C)

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

Different estrogens protect rat primary hippocampal neurons (A) and mouse clonal hippocampal cells (HT22) (B) against Aβ-induced cell death. Primary neurons and HT22 cells were plated and pretreated with the indicated estrogens (10 μm) for 20 hr. Then, cultures were challenged with 2 μm Aβ25–35 for an additional 20 hr, and neuronal survival was determined by performing MTT assays as previously described (9, 11, 12). C, HT22 cells were preincubated for 20 hr with increasing concentrations of ethinyl estradiol and then challenged by either 500 μm BSO ([triaf]), 2 μmAβ25–35 (•), or 1 mm glutamate (▪) for 20 hr, and MTT assays were performed. Results are expressed as the percentage of reduction of MTT relative to the corresponding control. The experimental data are presented as triplicate determinations across five independent experiments (mean ± standard error). Comparisons between cultures incubated with estrogens (or ethanol) alone and cultures treated with estrogens (or ethanol) plus toxin were made by analysis of variance followed by a Scheffe’s post hoctest. ∗, p < 0.01 (considered significant). A final concentration of 0.1% of the steroid solvent ethanol was not toxic to the cells and did not interfere either with the toxins or with the MTT reduction. An increase in cell survival caused by treatment with the estrogens alone was below 10% in these short time assays.

View this table:
  • View inline
  • View popup
Table 1

Protection of hippocampal neurons against oxidative stress-induced cell death by different estrogens

17-α-Estradiol, ethinyl estradiol, quinestrol, mestranol, and the catechol estrogens 2-OH-estradiol and 4-OH-estradiol were tested for their neuroprotective activity at 1 μm and 10 μm against BSO and H2O2 in mouse primary cortical neurons and against glutamate and H2O2 in HT22 cells. Estradiol is rapidly converted to 2-OH- and 4-OH-estradiol by an NADPH-dependent cytochrome P450-linked monooxygenase system in vivo (22). All tested estrogens that carry an OH group at the C3 position on the A ring of the steroid molecule afforded neuroprotection in these experimental paradigms at a concentration of 10 μm (Fig.3; Table 1). Again, steroid concentrations lower than 10 μm did not afford protection, as shown in detail for ethinyl estradiol (Fig. 2C). Steroid molecules with an ether-modified OH group at the C3 position (Fig. 1), such as the 17-α-ethinyl estradiols quinestrol (3-cyclopentyl ether) or mestranol (3-methyl ether) and testosterone with a keto group at the C3 position, did not prevent oxidative stress-induced cell death (Fig. 3; Table 1). After the glutamate challenge, PC microscopy revealed dramatic changes in cellular morphology, and PI stainings demonstrated cell death of the clonal hippocampal HT22 cells. Some experimental data argue for a receptor-independent pathway of neuroprotection by estrogens because 1) the addition of the estrogens 2 or 20 hr before the toxic challenge did not influence the protection afforded (data not shown), 2) high concentrations must be used to achieve a protective effect, 3) the addition of actinomycin D as the inhibitor of RNA synthesis did not block the protective effect (data not shown), 4) HT22 cells that lack endogenous estrogen receptors can be protected (12), and 5) 17-α-estradiol, which does not bind to estrogen receptors, is also neuroprotective.

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

17-α-Estradiol (17-α E), 17-β-estradiol (17-β E), and ethinyl estradiol (EE) prevent glutamate-induced intracellular accumulation of H2O2 and related peroxides and, ultimately, cell death in clonal hippocampal HT22 cells, whereas the ethinyl estradiol mestranol (M) is not protective. HT22 cells were plated in 60-mm dishes and either pretreated with the indicated estrogens (10 μm) for 20 hr or left untreated. Cells were challenged with 1 mm glutamate, and intracellular peroxide formation was determined after 6 hr using DCF stainings, as described in Experimental Procedures. After an additional 14 hr, parallel cultures were stained for dead cells, using PI at 5 μg/ml, as previously reported (12). Magnification of PC, PI, and DCF images is 100×.

Incubation of primary cortical neurons with Aβ and BSO, and treatment of HT22 cells with glutamate induced an intracellular accumulation of H2O2 and related peroxides (11) that can be detected with DCF stainings after 6 hr. This increase could be blocked by the preincubation of cells with different estrogens, as shown qualitatively in Fig. 3 and quantitatively in Table 1. Peroxides are precursors of the highly reactive, lipid-peroxidizing hydroxyl radical (19). Estrogens with an intact 3-OH group on the A ring significantly reduced the percentage of fluorescent cells after the glutamate challenge (p < 0.05), whereas quinestrol, mestranol, and testosterone were inactive and could not block these intracellular oxidative events, which is consistent with a lack of protective activity (Fig. 3; Table 1).

The hippocampus is a major target of neuronal cell death in neurodegenerative disorders such as AD (23). Organotypic hippocampal slice cultures from postnatal rats preserve the intrinsic connections and regional differentiation specific to the hippocampus in vivo and are frequently used for the investigation of neurotoxins (24). These cultures were established and pretreated with the different estrogens for 20 hr, followed by a strong oxidative challenge with 250 μm H2O2 for 24 hr that induced massive neuronal death in the gyrus dentatus region and the cornu ammonis region (Fig. 4A). The different 3-OH–containing estrogens protected the neuronal cells in the hippocampal slice, as exemplified by ethinyl estradiol, whereas its ether-modified derivatives quinestrol, mestranol, and testosterone were not protective (Fig. 4; data not shown).

Figure 4
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4

Ethinyl estradiol prevents H2O2-induced oxidative cell death in organotypic hippocampal slice cultures. Organotypic hippocampal slices were pretreated for 24 hr with either 10 μm mestranol (B), quinestrol (C) (both of which had ether-modified 3-OH groups on the A ring), or ethinyl estradiol (D) (intact 3-OH group on the A ring). A, A slice challenged with H2O2 without further pretreatment. Then, 250 μmH2O2 was added to the slices; after 24 hr, cell death was determined by using PI (5 μg/ml). Images were obtained by using a fluorescence microscope (40×) and UV filters. Red, PI-positive (dead) cells. Arrows, gyrus dentatus region;CA, cornuammonis region.  

In neuronal systems, estrogens can exert long term trophic actions and can stimulate the secretase metabolism of the amyloid β precursor protein via transcriptional activation after the binding of the estrogen receptor to estrogen-responsive elements on the DNA (25-27). These genomic actions of estrogen could potentially affect the AD risk. We report that estrogen and estrogen derivatives within the hydroxyl group in the C3 position on the A ring of the steroid molecule can also act as powerful neuroprotectants in an estrogen-receptor–independent short term manner because of to their antioxidative capacity. The concentrations required for a significant antioxidative neuroprotection in our in vitro system are higher than the estrogen levels that occur naturally in vivobut are consistent with those that have been previously shown to have antioxidant activity in different cellular and cell-free systems (6,12). Plasma concentrations of 17-β-estradiol are in the nanomolar range, depending on sex and menopausal status (28). Interestingly, 17-β-estradiol has been shown to be a more potent antioxidant inhibitor (IC50 = 21 μm) of iron-catalyzed lipid peroxidation in rat brain homogenates than vitamin E (IC50 = 30 μm) (29); the latter is currently being tested in a clinical AD trial. Nevertheless, as shown for the steroid compound RU486 after oral administration, micromolar steroid concentrations can be attained in vivo (30).

It is of great significance that the neuroprotective effect against oxidative stressors in the different neuronal in vitrosystems is also afforded by the nonestrogenic 17-α-estradiol, a compound that is biologically inactive with respect to binding to the estrogen receptor (20). In summary, our results pin down the neuroprotective activity of estrogens to the presence of the 3-OH group of the A ring in the steroid molecule and may therefore serve as a basis for the design and synthesis of other nonestrogenic antioxidants. One example could be the synthesis of estrogens with bulky alkyl substituents in both the 2- and 4-position on the A ring that do not bind to the estrogen receptor but that nevertheless exert an antioxidant potential (31).

Acknowledgments

We thank R. Rupprecht for helpful comments on the manuscript. We are grateful to P. Maher (Scripps Research Institute, LaJolla, CA) for supplying the HT22 cells.

Footnotes

    • Received November 6, 1996.
    • Accepted January 2, 1997.
  • Send reprint requests to: Christian Behl, Max Planck Institute of Psychiatry, Clinical Institute, 80804 Munich, Germany. E-mail: chris{at}mpipsykl.mpg.de

  • F.L. was supported by a postdoctoral fellowship from Institute National de la Santé et de la Recherche Médicale. This work was supported in part by a grant of the Wilhelm-Woort-Stiftung für Alternsforschung (C.B.).

Abbreviations

AD
Alzheimer’s disease
BSO
buthionine sulfoximine
DMEM
Dulbecco’s modified Eagle’s medium
PI
propidium iodide
PC
phase contrast
DCF
dichlorofluorescein
DCF-DA
2′,7′-dichlorofluorescein diacetate
MTT
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
HEPES
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Simpkins J. W.,
    2. Singh M., and
    3. Bishop J.
    (1994) The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer’s disease. Neurobiol. Aging Suppl. 15:195–197.
    OpenUrl
  2. ↵
    1. Paganini-Hill A. and
    2. Henderson V. W.
    (1994) Estrogen deficiency and risk of Alzheimer’s disease in women. Am. J. Epidemiol. 140:256–261.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. McEwen B. S.
    (1991) Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol. Sci. 12:141–147.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Clark J. H. and
    2. Peck E. J.
    (1979) Female sex steroids, receptors and function. Monogr. Endocrinol. 14:4–36.
    OpenUrlCrossRef
  5. ↵
    1. Paul S. M. and
    2. Purdy R. H.
    (1992) Neuroactive steroids. FASEB J. 6:2311–2322.
    OpenUrlAbstract
  6. ↵
    1. Ravi Subbiah M. T.,
    2. Kessel B.,
    3. Agrawal M.,
    4. Rajan R.,
    5. Abplanalp W., and
    6. Rymaszewski Z.
    (1993) J. Clin. Endocrinol. Metab. 77:1095–1097.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Parthasarathy S.,
    2. Steinberg D., and
    3. Witztum J. L.
    (1992) The role of oxidated low-density lipoproteins in the pathogenesis of atherosclerosis. Annu. Rev. Med. 43:219–225.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Coyle J. T. and
    2. Puttfarcken P.
    (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science (Washington D. C.) 262:689–695.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Yan S. D.,
    2. Cheng X.,
    3. Fu J.,
    4. Chen M.,
    5. Zhu H.,
    6. Roher A.,
    7. Slattery T.,
    8. Zhao L.,
    9. Nagashima M.,
    10. Morser J.,
    11. Migheli A.,
    12. Nawroth P.,
    13. Stern D., and
    14. Schmidt A. M.
    (1996) RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature (Lond.) 382:685–691.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Miyata M. and
    2. Smith J. D.
    (1996) Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nat. Gen. 14:55–61.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Behl C.,
    2. Davis J. B.,
    3. Lesley R., and
    4. Schubert D.
    (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:817–827.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Behl C.,
    2. Widmann M.,
    3. Trapp T., and
    4. Holsboer F.
    (1995) 17-Beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem. Biophys. Res. Commun. 216:473–482.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Goodman Y.,
    2. Bruce A. J.,
    3. Cheng B., and
    4. Mattson M.
    (1996) Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons. J. Neurochem. 66:1836–1844.
    OpenUrlPubMed
  14. ↵
    1. Glenner G. G.
    (1988) Alzheimer’s disease: its proteins and genes. Cell 52:307–308.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Choi D. W.
    (1992) Excitotoxic cell death. J. Neurobiol. 23:1261–1276.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Lafon-Cazal M.,
    2. Pietri S.,
    3. Culcasi M., and
    4. Bockaert J.
    (1993) NMDA-dependent superoxide production and neurotoxicity. Nature (Lond.) 364:535–537.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Murphy T. H.,
    2. Miyamoto M.,
    3. Sastre A.,
    4. Schnaar R. L., and
    5. Coyle J. T.
    (1989) Glutamate toxicity in a neural cell line involves inhibition of cystine transport leading to oxidative stress. Neuron 2:1547–1558.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Davis J. B. and
    2. Maher P.
    (1994) Protein kinase C activation inhibits glutamate-induced cytotoxicity in a neuronal cell line. Brain Res. 652:169–173.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Halliwell B.
    (1989) Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? Free Radical Biol. Med. 7:645–651.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Gorski J. A
    (1994) hindsight view of early studies on the estrogen receptor: a personal history. Steroids 59:240–243.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Yankner B. A.,
    2. Duff L. K., and
    3. Kirschner D. A.
    (1990) Neurotrophic and neurotoxic effects of myeloid beta protein: reversal by tachykinin neuropeptides. Science (Washington D. C.) 250:279–282.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Jellinck P. H.,
    2. Michnovicz J. J., and
    3. Bradlow H. L.
    (1991) Influence of indole-3-carbinol on the hepatic microsomal formation of catechol estrogens. Steroids 56:446–450.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Braak H. and
    2. Braak E.
    (1991) Neuropathological staging of Alzheimer-related changes. Acta. Neuropathol. 82:239–259.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Diekmann S.,
    2. Nitsch R., and
    3. Ohm T. G.
    (1994) The organotypic entorhinal-hippocampal complex slice culture of adolescent rats. A model to study transcellular changes in a circuit particularly vulnerable in neurodegenerative disorders. J. Neural Transm. Suppl. 44:61–71.
    OpenUrlPubMed
  25. ↵
    1. Ferreira A. and
    2. Caceres A.
    (1991) Estrogen-enhanced neurite growth: evidence for a selective induction of tau and stable microtubules. J. Neurosci. 11:392–402.
    OpenUrlAbstract
  26. ↵
    1. Jaffe A. B.,
    2. Toran-Allerand C. D.,
    3. Greengard P., and
    4. Gandy S. E.
    (1994) Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J. Biol. Chem. 269:13065–13068.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Honjo H.,
    2. Tanaka K.,
    3. Kashiwagi T.,
    4. Urabe M.,
    5. Okada H.,
    6. Hayashi M., and
    7. Hayashi K.
    (1995) Senile dementia—Alzheimer’s type and estrogen. Hormone Metab. Res. 27:204–207.
    OpenUrlPubMed
  28. ↵
    1. Baulieu E.-E. and
    2. Kelly P. A.
    1. Milgrom E.
    (1990) Steroid hormones. in Hormones—From Molecules to Disease, eds Baulieu E.-E. and Kelly P. A. (Chapman and Hall, New York), pp 387–437.
  29. ↵
    1. Hall E. D.,
    2. Pazara K. E., and
    3. Linseman K. L.
    (1991) Sex differences in postischemic neuronal necrosis in gerbils. J. Cereb. Blood Flow Metab. 11:292–298.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Heikinheimo O. and
    2. Kekkonen R.
    (1993) Dose-response relationships of RU-486. Ann. Med. 25:71–76.
    OpenUrlPubMed
  31. ↵
    1. Miller C. P.,
    2. Jirkovsky I.,
    3. Hayhurst D. A., and
    4. Adelman S. J.
    (1996) In vitro antioxidant effects of estrogens with a hindered 3-OH function on the copper-induced oxidation of low density lipoprotein. Steroids 61:305–308.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 51 (4)
Molecular Pharmacology
Vol. 51, Issue 4
1 Apr 1997
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Neuroprotection against Oxidative Stress by Estrogens: Structure-Activity Relationship
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
Citation Tools
Rapid CommunicationAccelerated Communication

Neuroprotection against Oxidative Stress by Estrogens: Structure-Activity Relationship

Christian Behl, Thomas Skutella, Frank Lezoualc’H, Anke Post, Martina Widmann, Christopher J. Newton and Florian Holsboer
Molecular Pharmacology April 1, 1997, 51 (4) 535-541; DOI: https://doi.org/10.1124/mol.51.4.535

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Rapid CommunicationAccelerated Communication

Neuroprotection against Oxidative Stress by Estrogens: Structure-Activity Relationship

Christian Behl, Thomas Skutella, Frank Lezoualc’H, Anke Post, Martina Widmann, Christopher J. Newton and Florian Holsboer
Molecular Pharmacology April 1, 1997, 51 (4) 535-541; DOI: https://doi.org/10.1124/mol.51.4.535
Permalink:
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results and Discussion
    • Acknowledgments
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • AMPK Activation Alters Stress Granule Assembly
  • Cryo-EM Analysis of the Human P-glycoprotein ATPase Cycle
  • Cryo-EM Studies with Glutamate Dehydrogenase
Show more Accelerated Communication

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2017 by the American Society for Pharmacology and Experimental Therapeutics